Poll results

CRO should stand for contract research organisation say readers

By Gareth Macdonald

- Last updated on GMT

Outsourcing-pharma.com readers want the acronym CRO to stand for 'contract research organisation' according to the results of a snap poll we ran yesterday.

Prompted by a debate on Linkedin​ we decided to ask readers how the industry should define CRO and whether the term “collaborative” should be considered as an alternative to reflect the closer strategic relationships many services firms have with their clients.

Here are the results:

 

pollresultsfinal

(Thanks to all 70 readers who took part – 61% voted for contract research organisation; 21% backed clinical research organisation; and 17% per cent opted for the Collaborative Research definition.)

While the survey was only small the results do suggest the contract research sector wants to continue to be viewed as having a solid business-oriented relationship with the drug industry (some respondents on the Linkedin suggested ‘collaborative’ may favoured by scientists more focused on research than business.)

CRO, CMO or CDMO?

Outsourcing-pharma.com was also contacted Pharmatek Laboratories’ president Tim Scott, who is chairman of the CRO committee set up by Southern California, US-based life sciences industry group Biocom.

Scott told us that: “With regard to the CRO debate, BIOCOM established a committee group for service providers.  we called the group simply CRO. While we recognized that there are CMOs, CROs, CSOs and CDMOs, we chose the CRO moniker because it was widely recognized as life science service providers. 

That said, the committee feels pretty strongly that the acronym, CRO, most often represents the clinical research companies that provide clinical support for clinical trial management​.”

He also rejected the idea​ that terms CRO and CMO are starting to overlap, which is an idea we examined in a story earlier this year.   

Manufacturers of drug product rarely, if at all, have involvement in managing clinical trials and are happy to call themselves CMO's.  Many that are also involved in formulation development prefer the name CDMO so as to better describe their involvement in the broader development process​.” 

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers